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INTRODUCTION 
 
The exocrine and endocrine pancreata are closely linked both anatomically and 
physiologically. Pathological conditions in the exocrine tissue can cause an impairment of the 
endocrine function and vice versa. Pancreatic exocrine insufficiency (PEI) is defined by a 
deficiency of exocrine pancreatic enzymes resulting in an inability to maintain normal 
digestion. 
Chronic pancreatitis (CP) is the most common etiology of PEI. Gastrointestinal and 
pancreatic surgical resections, cystic fibrosis, obstruction of the main pancreatic duct (e.g. 
pancreatic and ampullary tumors), decreased pancreatic stimulation (e.g. celiac disease), or 
acid-mediated inactivation of pancreatic enzymes (e.g. Zollinger-Ellison syndrome) can lead 
to PEI. It has been demonstrated to be present in a considerable percentage (10–74%) of 
patients with diabetes mellitus (DM). PEI has been indicated by direct or indirect pancreatic 
function tests to be present in about 50% of type 1 and 30–50% of type 2 diabetes mellitus 
(T2DM) cases. Steatorrhoea was observed in about 60% of patients with diabetes mellitus and 
fecal elastase <100 μg/g, indicating relevant, severe damage of the exocrine function. 
The level of pancreatic elastase-1 (PE-1) has been reported to be lower or not to differ 
in patients with HbA1c >8% relative to those with HbA1c ≤8%. However, for the proper 
management of DM and to prevent microvascular complications, a goal should be to maintain 
HbA1c <7%. 
Previous studies have raised the possibility that pancreatic enzyme replacement 
therapy (PERT) in patients with DM and PEI may improve glucose metabolism, PEI related 
symptoms, nutritional parameters and incretin response. However, the significance of an 
exocrine dysfunction in DM has recently been questioned, and no beneficial effect of PERT 
on the glucose metabolism was observed in patients with insulin treatment for DM, although a 
reduction in mild and moderate hypoglycemia was demonstrated. 
It is a well-known fact that insulin resistance, diabetes, and obesity cause fat 
accumulation in many organs, including the liver (nonalcoholic fatty liver disease [NAFLD]), 
pancreas (nonalcoholic fatty pancreas disease [NAFPD]), and pericardium (pericardial 
adipose tissue [PAT]). The worldwide prevalence of NAFLD ranges widely from 6.3% to 
33% with a median of 20%, depending on the kind of assessment methods used. There is a 
high prevalence of NAFLD in patients with T2DM (64–69%) and dyslipidemia (20–81%). 
Obesity, T2DM, and dyslipidemia are risk factors for the development of NAFLD. The 
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incidence rate of prediabetes mellitus (pre-DM) is as high as 93.3% in NAFLD, so pre-DM is 
a more important predictor of NAFLD than metabolic syndrome. If left untreated, NAFLD 
may progress through steatohepatitis to cirrhosis and hepatocellular carcinoma. 
NAFPD, defined as pancreatic fat accumulation, is a less well-studied phenomenon. 
Fatty pancreas is a common ultrasound finding with increased echogenicity of the 
parenchyma due to fat accumulation. Previous studies have suggested a 16%–35% prevalence 
of fatty pancreas in the general population. It seems that age, obesity, hyperglycemia, and 
dyslipidemia are risk factors for NAFPD. It may increase the risk for the development of 
metabolic syndrome by causing inflammation, impaired pancreatic beta cell function, and 
finally hyperglycemia. This relationship may explain the presence of T2DM in 6.9–12.6% of 
patients with NAFPD. 
It has been demonstrated that obesity may lead to pancreatic ductal adenocarcinoma 
through NAFPD. Evidence suggests that NAFPD plays a role in T2DM, pancreatic exocrine 
dysfunction, acute pancreatitis, pancreatic cancer, and the formation of pancreatic fistulas 
after pancreatic surgery. 
NAFLD and NAFPD are associated with each other because pancreatic fat formation 
is related to NASH and is a significant predictor of the presence of NAFLD. The elevation of 
liver transaminases may suggest the presence of NAFLD or NASH. Ultrasonography (US) 
and transient elastography are currently the most appropriate imaging modality for NAFLD 
screening, and liver biopsy is the ‘‘gold standard’’ for characterizing liver histology in 
patients with NAFLD. In contrast to the liver, no biochemical marker is available for 
diagnosing NAFPD. Further, as the pancreas is a retroperitoneal organ, a pancreatic biopsy is 
more cumbersome and may be accompanied by more sampling errors and complications 
compared with a liver biopsy. Visualizing the pancreas by US is more difficult, and the 
sensitivity and specificity of US in detecting NAFPD are hampered by obesity and bloating. 
In prediabetic and T2DM patients, the amount of PAT is significantly higher compared with 
that in normoglycemic patients. Previous reviews have demonstrated that, besides epicardial 
adipose tissue, PAT is another risk factor for the development of cardiovascular disease in 
T2DM patients. 
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AIMS 
 
I. to assess the possible relationship between T2DM with poor glycemic control 
(HbA1c ≥7.0%), an exocrine pancreatic insufficiency and alterations in pancreatic 
morphology; 
II. to evaluate the incidence rate of NAFLD, NAFPD and PAT size, and the effect of 
metformin therapy on NAFLD, NAFPD and PAT in new-onset T2DM (NODM); 
III. to provide an overview of the current concepts of PEI in diabetes mellitus by 
performing a systematic review. 
PATIENTS AND METHODS 
 
The thesis is based on two clinical studies and a systematic review. 
I. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with 
poor glycemic control. 
Consecutive patients with T2DM followed-up in the diabetes outpatient clinic of the 
First Department of Internal Medicine, University of Szeged were prospectively recruited into 
the study between April 1, 2012 and June 30, 2013. Fasting blood glucose and serum HbA1c 
level were measured at the time of recruitment. The patients were divided into two groups, 
depending on the serum level of HbA1c: Group A: patients with poor glycemic control 
(glycosylated hemoglobin [HbA1c] ≥7%), and Group B: patients with good glycemic control 
(HbA1c <7%). The pancreatic exocrine function was evaluated via the measurement of fecal 
PE-1, and morphological examinations were performed on the pancreas. 
The diagnosis of DM was made in accordance with the criteria of the American 
Diabetes Association (ADA) [14]. CP was diagnosed only when both the morphological and 
functional diagnostic criteria were fulfilled. Cases with type 3cDM, i.e. diabetes secondary to 
exocrine pancreatic diseases, were excluded. The patients were not operated on the pancreas. 
Fecal PE-1 was determined through the use of monoclonal antibodies (ScheBo Biotech AG, 
Giessen, Germany). Abdominal US and computer tomography (CT) were performed to detect 
the characteristic morphological features of CP. 
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II. Evaluation the incidence rate of NAFLD, NAFPD and PAT size, and the effect 
of metformin therapy on NAFLD, NAFPD and PAT in NODM. 
The diagnosis of T2DM was made in accordance with the ADA criteria. NODM is 
defined as DM diagnosed within the past 1 month before the date of enrollment. Patients were 
only on a low-carbohydrate diet and received no hypoglycemic agents before inclusion. 
Exclusion criteria consisted of any pancreatic, liver, or cardiovascular disease, inherited 
disorders of fat metabolism, pregnancy, malignant disease, antidiabetic medication, or alcohol 
consumption in patients’ medical records. NODM patients received no other new drugs 
beyond 1000 mg metformin twice daily after inclusion. However, a hypolipidic diet was 
recommended to patients with elevated lipid levels. 
The follow-up period was 4 months. CT and laboratory tests (serum triglyceride, 
cholesterol, insulin level, fasting blood glucose, and HbA1c) were performed before the 
beginning of metformin therapy and 4 months afterward. Homeostatic model assessment-
estimated insulin resistance (HOMA-IR) was also calculated. PAT size and the amount of fat 
in the pancreas and liver were determined by X-ray attenuation rate during unenhanced CT 
examination (Hounsfield unit [HU]). Each region of interest (ROI) in the liver, pancreas, and 
spleen was a round area of 1.0 cm2 as a marker of the degree of attenuation. In the case of 
PAT, measurements were performed in one dedicated slice at the junction of the inferior vena 
cava and right atrium. ROIs were identified in segment VII of the liver, along the 
diaphragmatic surface of the spleen and in the body of the pancreas. Mean density was 
calculated, and General Electric Centricity PACS software was used to determine the values. 
NAFLD and NAFPD were defined when the liver-to-spleen or pancreas-to-spleen attenuation 
ratio was <1. 
 
III. Current concepts of PEI in diabetes mellitus. Systematic review. 
 
The systematic review was conducted following the preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. A systematic 
search was performed in 3 databases, Pubmed, Embase and Cohraine Library. The search 
included the following MESH terms: “diabetes mellitus” AND “pancreatic function” OR 
“pancreatic exocrine insufficiency” OR “fecal elastase” OR “secretin” OR “cholecystokinin” 
OR “steatorrhea” or “pancreatic enzyme replacement therapy”. The search was limited to 
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human data and to full text English articles if appropriate. The latest date searched was 
conducted on the 31th of January 2018.  
Selection of the studies was conducted by two investigators (Gábor Zsóri and László 
Czakó) separately. Clinical studies were eligible provided that they reported the data of 
pancreatic exocrine function in adult patients suffering from type 1 and 2 diabetes mellitus. 
Publications about type 3cDM were excluded. Duplicates, repeated publications, publications 
available only in abstract form, and review papers were excluded. Moreover, articles with 
inappropriate study design and patient inclusion criteria were also excluded from this 
systematic review. Remaining studies were further analyzed in full text. The reference list of 
obtained articles was also checked for additional articles. If differences were found in the 
reviewer's judgment, then a committee of three other researchers was invited to draw a 
conclusion. 
RESULTS 
 
I. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with 
poor glycemic control 
A total of 101 type 2 diabetic patients were included into the study: 59 (25 male, 34 
female, mean age: 63.6±10.4 years, range: 42–89 years) in Group A and 42 (22 male, 20 
female, mean age: 57.1±11.2 years, range: 30–83 years) in Group B. 2 patients had 
autoimmune disorders, both suffered from rheumatoid arthritis, one in Group A and one in 
Group B. In group A 12 patients were on oral antidiabetic therapy, while the other 47 patients 
received insulin treatment. The same in Group B were 23 and 15, respectively, and the rest 4 
patients were on diet only. The range of HbA1c was 7.0–11.6% in Group A and 5–6.9% in 
Group B. The body mass index (BMI) of the patients were comparable in the two groups 
(p=0.278). However, the mean age was significantly higher (p<0.008), and the duration of 
DM was significantly longer (p<0.006) in Group A as compared to Group B. 
The fecal PE-1 concentration in Group A was normal in 45 patients (76.3%), while 11 
(18.6%) exhibited a mild and 3 (5.1%) a severe PEI. In Group B, the PE-1 concentration was 
normal in 39 subjects (92.9%), while 3 (7.1%) displayed a mild PEI, and none a severe 
insufficiency. The prevalence of abnormal PE-1 concentration was significantly different 
between Group A and B (23.7% vs. 7.1%; p=0.033). The PE-1 level was significantly lower 
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in Group A than in Group B (385.9±171.1 vs. 454.6±147.3 µg/g, p<0.04, odds ratio 
[OR]=4.0). The PE-1 level was not correlated with HbA1c (r=-0.132, p=0.187), the duration 
of DM (r=-0.046, p=0.65), age (r=0.010, p=0.921), or BMI (r=0.203, p=0.059). 
 
II. Evaluation the incidence rate of NAFLD, NAFPD and PAT size, and the effect 
of metformin therapy on NAFLD, NAFPD and PAT in NODM 
Seventeen patients with NODM (male: 8; female: 9; mean age: 55.3±10.8 years; BMI: 
31.8±5.1 kg/m2) were involved in this prospective study. The control group comprised 10 
healthy subjects (male: 6; female: 4; mean age: 53.9±13.8 years; BMI: 30.0±4.7 kg/m2) 
without DM, without the presence of any pancreatic, liver, or cardiovascular disease, or 
history of alcohol consumption and matched for age, sex, BMI, and serum lipids  
Fasting blood glucose, HbA1c, serum insulin and cholesterol, and HOMA-IR 
decreased significantly after metformin therapy compared with the baseline values. However, 
serum triglyceride and BMI did not change. 
NAFLD was diagnosed in 64.7% (11 out of 17) of the patients with NODM and in 
10% of the control subjects based on the diagnostic criteria. The amount of fat in the liver was 
significantly higher in NODM patients with NAFLD than in those without it (25.2±12.7 vs. 
55.6±9.3 HU). The serum cholesterol level was significantly higher in patients without 
NAFLD as compared with patients with the disease in the NODM group (p=0.002). BMI, 
serum triglyceride, fasting blood glucose level, HbA1c, and liver enzymes were not 
significantly different between patients with and without NAFLD. 
The radiation absorption of the liver was significantly lower in patients with NODM 
compared with the control group (32.3±17.7 vs. 53.1± 8.3HU [p =0.001]) and significantly 
increased after metformin therapy compared with the baseline values (32.3±17.7 vs. 
47.3±12.1 HU [p=0.026]). Only six patients (35.3%) had NAFLD after the 4-month 
metformin therapy according to the diagnostic criteria. 
NAFPD was diagnosed in 82.3% (14 out of 17) of the patients with NODM and in 
20% of the control subjects based on the diagnostic criteria. The amount of fat in the pancreas 
was significantly higher in the NODM patients with NAFPD than in those without it 
(30.2±6.9 vs. 45.4±3.9 HU [p<0.001]). The radiation absorption of the pancreas was 
significantly lower in the patients with NODM compared with the control group (34.0±7.9 vs. 
39.4±7.8 HU [p=0.04]) but did not change significantly after the 4-month metformin 
treatment (34.0±7.9 vs. 37.7±10.2 HU [p=0.178]). 
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PAT size was significantly larger in the patients with NODM compared with the 
control group (2143.1±1036 vs. 1223.9±312.9 mm2 [p=0.008]) and did not change 
significantly after the metformin treatment (2143. ±1036 vs. 2048.2±997 mm2 [p=0.798]). 
 
III. Current concepts of PEI in diabetes mellitus. Systematic review 
 
Database searches yielded altogether 1055 articles (EMBASE: 67; PubMed: 701; 
Cochrane: 287). 
 
Prevalence of exocrine pancreatic insufficiency in diabetes mellitus 
 
There have been numerous reports in recent decades on PEI in patients with diabetes 
mellitus. In the early studies, pancreatic exocrine function was assessed with the gold-
standard method of direct pancreatic function tests (pancreozymin-secretin test). PEI was 
revealed in 52.4% (18–100%) of the cases. However, these studies were only limited to a 
small number of patients because direct pancreatic function tests are invasive, time-
consuming and expensive. Therefore, a less invasive, cost-effective test was needed to 
evaluate pancreatic exocrine function in DM. Nowadays, therefore, fecal elastase-1 (FE-1) 
measurement has become a screening tool in determining PEI. The prevalence of PEI has 
been demonstrated with FE-1 measurement with an average of 40% (26–74%) in type 1 
diabetes and with an average of 27% (10–56%) in type 2 diabetes. 
 
Prevalence of morphologic changes of the exocrine pancreas in diabetes mellitus 
 
Several studies have examined the morphologic changes of the exocrine pancreas in 
DM. In nearly 50% of type 1 DM patients, the pancreas is atrophic and fibrotic, with fatty 
infiltration and loss of acinar cells on histological examination. Reduced pancreas size in 
patients with DM was demonstrated by abdominal US, CT or MRI. Ductal changes are 
detected by endoscopic retrograde cholangiopancreatography (ERCP) in 76% of diabetics. 
Interestingly, these ductal changes do not correlate with DM type, DM duration or age. 
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Pathophysiology of PEI in diabetes mellitus 
 
Pancreas atrophy is a related event in DM and plays a central role in the development 
of PEI. (1) Insulin has a trophic effect on pancreatic acinar tissue through the insulin-acinar 
portal system, so its decreased locally high level could lead to pancreatic atrophy. (2) Acute 
hyperglycemia was demonstrated to inhibit basal and cholecystokinin-stimulated pancreatic 
enzyme secretion with an insulin-independent mechanism. (3) Pancreatic stellate cells (PSCs) 
play a pivotal role in pancreatic fibrosis. Hyperglycemia was demonstrated to promote 
proliferation and activation of PSCs and to stimulate collagen production of PSCs via the 
protein kinase seCp38 mitogen-activated protein kinase pathway, resulting in pancreatic 
fibrosis. (4) The islet hormones (e.g. glucagon and somatostatin) can regulate exocrine tissue, 
so the lack of these hormones causes dysregulation of enzyme synthesis and resultant 
exocrine insufficiency. (5) Diabetic microangiopathy leads to insufficient perfusion through 
local microangiopathy, resulting in ischemia of the exocrine pancreas, which could lead to 
pancreatic fibrosis, atrophy and PEI. (6) Autonomic neuropathy may give rise to impaired 
enteropathic reflexes and PEI. Moreover, (7) viral infections, (8) autoimmunity, or (9) genetic 
changes, as single-base deletion in the variable number of tandem repeats containing exon 11 
of the carboxyl ester lipase gene could increase simultaneous damage to exocrine and 
endocrine tissue. 
Nowadays the role of signaling proteins in pancreatic inflammation and diabetes 
induced pancreatic insufficiency is getting more attention. In a previous study the levels of 
total PKB, p70S6K, 4 E-BP1, ERK1/2, and NF-kappaB in the diabetic pancreas compared to 
control were significant decreased, however, the phosphorylation of p70S6K1, 4 E-BP1, 
ERK1/2, and protein ubiquitination were increased significantly compared to control group. 
Presumable, that these factors are liable for decreased enzyme synthesis and pancreatic 
atrophy. 
 
Symptoms of PEI in diabetes mellitus 
 
The main clinical symptoms of PEI are due to the maldigestion and malabsorption of 
fat, including steatorrhea, abdominal pain, flatulence, bloating and weight loss. Although PEI 
seems to be frequent in DM, data on the occurrence of the symptoms of PEI in diabetes are 
limited. Gastrointestinal (GI) symptoms are common (27–87%) in patients with type 1 and 
type 2 DM. In a recent study 24% of diabetic patients had one or more GI symptoms 
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consistent with a diagnosis of PEI (Bristol stool type 5–7, steatorrhea or weight loss). Among 
these patients, 42% had a low FE-1, indicating PEI. It can be concluded that FE-1 screening is 
beneficial in patients with GI symptoms, suggesting the presence of PEI.  
 
Diagnosis of PEI 
 
PEI is suggested by clinical symptoms or poor glycemic control despite an adequate 
diet, antidiabetic therapy and patient adherence. Determination of FE-1 is the most convenient 
way to diagnose PEI. Decreased FE-1 concentration has previously been demonstrated to be a 
sensitive method in moderate and severe PEI (sensitivity: 87% and 95%, respectively) and 
correlated significantly with the direct pancreatic function test, fat digestion, and the 
Cambridge severity classification of chronic pancreatitis. PEI can also be diagnosed with a 
13C mixed triglyceride breath test by measuring the concentration of 13CO2 in expired air 
after administering the radiolabeled test meal containing a known amount of fat. Coefficient 
of fat absorption (CFA) is another gold standard test for PEI, although it has not been 
evaluated in DM. 
Direct pancreatic function tests are considered the gold standard in diagnosing PEI, 
and they definitely have advantages over indirect tests. However, direct tests are rather time-
consuming and expensive to perform, very inconvenient for patients, and only available in a 
few academic centers. 
 
Therapy of PEI 
 
PERT is applied in PEI to prevent the symptoms of malabsorption, such as steatorrhea, 
and to provide physiologic nutrition by correcting maldigestion. Only a very limited number 
of publications have investigated the effectiveness of PERT in PEI associated with diabetes, 
and the results are contradictory. Recent guidelines recommend a starting dose of PERT to be 
50 000 IU lipase per main meal and 25 000 IU per snack, and this may be titrated up 
according to symptoms. However, recent evidence suggests that even this dose of PERT may 
not be sufficient to normalize nutrition. 
Nutrient-induced glucose-dependent insulinotropic polypeptide (GIP) response is 
diminished in patients with PEI. PERT has been demonstrated to reverse an impaired GIP 
response and therefore to restore the incretin effect of fat. This effect of PERT may be 
beneficial in the glycemic control of diabetic patients with PEI. 
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However, while diabetic patients with reduced FE-1 may not complain about PEI-
related gastrointestinal symptoms, they still might suffer from qualitative fat maldigestion, for 
example, lack of vitamin D, as has been proposed recently. Furthermore, patients with 
diabetes mellitus have an increased risk of bone fractures. PERT has been demonstrated to 
increase serum vitamin D level in diabetic patients with PEI, an effect which would be 
beneficial to reducing the increased risk of bone fracture. 
The currently available evidence is limited to answering the question of whether PERT 
is efficacious in glycemic control in patients with diabetes and PEI. Without doubt, there is a 
need for further randomized clinical trials in the field. For the moment, we can only suggest 
searching for PEI in diabetic patients by looking for abdominal symptoms that may be related 
to PEI and by analyzing serum nutritional factors and vitamin D level. If the test is positive, a 
trial of PERT is recommended. The response of abdominal symptoms, serum nutritional 
factors and parameters of glucose metabolism should be followed. In the case of positive 
response, long-term PERT is suggested. 
 
NEW RESULTS ESTABLISHED IN THE THESIS 
 
I. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with 
poor glycemic control 
 
1) PEI demonstrated by fecal PE-1 determination is more frequent in T2DM patients with 
poor glycemic control. 
2) The impaired exocrine pancreatic function cannot be explained by an alteration in the size 
of the pancreas or by pancreatic steatosis. 
 
II. Evaluation the incidence rate of NAFLD, NAFPD and PAT size, and the effect 
of metformin therapy on NAFLD, NAFPD and PAT in NODM 
 
1) NAFLD, NAFPD, and increased PAT were detected in the majority of patients with 
NODM. 
2) Metformin therapy decreased the amount of fat in the liver in parallel with an improvement 
in the metabolic parameters and may, thus, be beneficial for preventing the late 
consequences of NAFLD. 
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III. Current concepts of PEI in diabetes mellitus. Systematic review 
 
1) PEI is detected in almost 50% of diabetic patients by direct or indirect pancreatic function 
tests. 
2) Morphological changes in the pancreas is revealed in approximately 50% of diabetic 
patients. 
3) Determination of FE-1 is the most appropriate methods to diagnose PEI in symptomatic 
diabetic patients 
4) The currently available evidence is limited to answering the question of whether PERT is 
efficacious in glycemic control in patients with diabetes and PEI. 
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